Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
NRG Oncology
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Massachusetts General Hospital
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
BeiGene
University Health Network, Toronto
Eli Lilly and Company
Amgen
Washington University School of Medicine
GlaxoSmithKline
Gilead Sciences
University of Oklahoma
EMD Serono
Merck Sharp & Dohme LLC
Takeda
EMD Serono
Merck Sharp & Dohme LLC
Takeda
Hoffmann-La Roche
Bristol-Myers Squibb
Fox Chase Cancer Center
EMD Serono
Merck Sharp & Dohme LLC
Daiichi Sankyo
Takeda
Gilead Sciences
Takeda
Merck Sharp & Dohme LLC
Tracon Pharmaceuticals Inc.
GlaxoSmithKline
AstraZeneca
Eli Lilly and Company
AstraZeneca
University of Massachusetts, Worcester
Takeda
AstraZeneca
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
MedImmune LLC
Hoffmann-La Roche
EMD Serono
Merrimack Pharmaceuticals
Boehringer Ingelheim